Endocrine Abstracts

Background: The NordiNet® International Outcome Study (IOS) (NCT00960128), a non-interventional study (2006–2016), assessed the effectiveness and safety of real-life treatment with Norditropin®. Out of 20,548 enrolled patients, 20,195 (paediatric/adult; 17,711/2484) were included in the full analysis set (FAS) and 12,938 (11,967/971) in the effectiveness analysis set (EAS). Outcomes were assessed in children with growth hormone deficiency (...

Introduction: Growth hormone (GH) replacement therapy is safe and confers significant benefits in body composition, bone health, cardiometabolic risk factors, and quality of life in adults with GH deficiency. However, longer term safety and efficacy data are limited by the lack of consistency in data collection between studies. The study aim was to develop a simple global register by standardising and developing a minimum data set (MDS) to facilitate international collection o...